Lantheus Holdings, Inc. logo LNTH - Lantheus Holdings, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 13
HOLD 4
SELL 0
STRONG
SELL
0
| PRICE TARGET: $103.50 DETAILS
HIGH: $115.00
LOW: $94.00
MEDIAN: $102.50
CONSENSUS: $103.50
UPSIDE: 0.49%

About Lantheus Holdings, Inc. (https://www.lantheus.com)

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Key Executives

NAME TITLE DOB SALARY
Ludger Dinkelborg Head of Research & Development 1963 $13,659,644 USD
Brian A. Markison Strategic Advisor 1959 $1,440,685 USD
Robert J. Marshall Jr. Chief Financial Officer & Treasurer 1967 $991,665 USD
Jean-Claude Provost Chief Science Officer 1963 $894,790 USD
Thomas Reiner Chief Science Officer $894,790 USD
Daniel Niedzwiecki Chief Administrative Officer, General Counsel & Corporate Secretary 1977 $763,085 USD
Amanda Morgan Chief Commercial Officer 1979 $677,449 USD
Mary Anne Heino Interim CEO & Executive Chairperson 1960 $673,968 USD
Dorothy Barr Senior Vice President of Manufacturing & Technical Operations
Kimberly Brown Chief Accounting Officer 1991
Lee Anne Howe Chief Information Officer
Mark Richard Kinarney Vice President of Investor Relations
Neil Holland Vice President of Business Insights & Operations

Company Peers

Peer analysis pending, check back in 1-2 minutes.